AB Managed Volatility Equities (ACM0006AU) Report & Performance

What is the AB Managed Volatility Equities fund?

The AB Managed Volatility Equities Fund is designed for equity investors seeking lower volatility, reduced downside risk in falling equity markets, and the potential for long-term capital growth and some income, including franked Australian dividend income. The Fund implements a managed-volatility equities strategy that aims to reduce volatility by identifying, and investing in, high-quality listed equity securities that have reasonable valuations, high-quality cash flows and relatively stable share prices.

  • The Fund invests mainly in Australian Securities Exchange (ASX)–listed shares, with up to 20% of its assets in global developed-market shares, and has the ability to hold up to 20% in cash, for example as a short-term defensive measure at times of heightened equity market volatility.
  • The Fund does not always hedge the foreign currency exposures of its global equity assets to Australian dollars, and the investment manager has the discretion to determine the extent to which any foreign currency exposure is reduced or removed. For example, the investment manager may decide not to remove a foreign currency exposure if it believes it offers defensive characteristics that would assist in lowering the volatility of the Fund.
  • The AB Managed Volatility Equities Fund—MVE Class (the “MVEClass”) aims to achieve returns that exceed the S&P/ASX 300 Accumulation Index after fees over the medium to long term.

Growth of $1000 Investment Over Time

Performance Report

Peer Comparison Report

Peer Comparison Report

Latest News & Updates For AB Managed Volatility Equities

AB Managed Volatility Equities Fund Commentary July 31, 2023

• In July, the MVE – Class underperformed its benchmark, the S&P/ ASX 300 Index, which was up 2.89% in Australian-dollar terms.

Detractors

• Pharmaceutical company Merck underperformed generally in line with healthcare on limited stock-specific news.

• A lack of exposure to “big four bank” CBA detracted. After weak bank results in February and May, the banking sector generally outperformed in July on limited news. We see margin pressure continuing to intensify as high rates induce customers to switch from low or no interest deposits to more attractive products.

• After a strong period of performance year to date, diagnostics company Sonic Healthcare detracted as it gave up some gains during the month. We continue to like Sonic for its strong balance sheet, stable cash flows and an attractive pipeline of bolt-on acquisitions.

Contributors

• An underweight to biotech company CSL contributed as a competitor to its flagship immunoglobulin franchise released positive phase 3 clinical trial data showing comparable efficacy in a major indication.

• Evolution Mining contributed as gold prices increased approximately US$40 per ounce in July, helping gold producers. In addition, Evolution reported fourth-quarter production results and provided FY:24 guidance that topped some expectations.

• Not holding asset manager Macquarie contributed as it downgraded its outlook for 2024 earnings, primarily due to lower deal flow and weaker commodity income.

READ HISTORICAL PERFORMANCE COMMENTARIES

Product Snapshot

  • Performance Review
  • Product Overview
  • Peer Comparison
  • Product Details

Performance Review

Fund Name Last Month
? Returns after fees in the most recent (last) month).
3 Months Return
? Returns after fees in the most recent 3 months.
1 Year Return
? Trailing 12 month returns.
3 Years Average Return
? Average Annual returns from the last 3 years.
Since Inc. Average Return
? Average (annualised) returns since inception
1 Year Std. Dev. (Annual)
? The standard deviation (or annual volatility) of the last 12 months.
3 Years Std. Dev. (Annual)
? The average standard deviation (or annual volatility) from the last 3 years.
Since Inc. Std. Dev. (Annual)
? The average standard deviation (or annual volatility) since the fund inception.
1 Year Max Drawdown
? The maximum drawdown in the last 12 months - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
3 Year Max Drawdown
? The maximum drawdown in the last 36 months - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
Since Inc. Max Drawdown
? The maximum drawdown since inception - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
AB Managed Volatility Equities0.51%5.21%11.18%3.32%8.65%7.74%9.73%9.86%-4.14%-10.35%-17.06%

Product Overview

Peer Comparison

Product Details

Product Due Diligence

What is AB Managed Volatility Equities

AB Managed Volatility Equities is an Managed Funds investment product that is benchmarked against ASX Index 200 Index and sits inside the Domestic Equity - Large Cap Neutral Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The AB Managed Volatility Equities has Assets Under Management of 1.01 BN with a management fee of 0.55%, a performance fee of 0.00% and a buy/sell spread fee of 0.5%.

How has the investment product performed recently?

How is risk measured in this investment product?

What is the relative performance of the investment product?

Does the investment product produce Alpha over its Peers?

What are similar investment products?

What level of diversification will AB Managed Volatility Equities provide?

How do I compare the investment product with its peers?

How do I compare the AB Managed Volatility Equities with the ASX Index 200 Index?

Can I sort and compare the AB Managed Volatility Equities to do my own analysis?

Has the AB Managed Volatility Equities been independently verified by SMSF Mate?

How can I invest in AB Managed Volatility Equities?

How do I get in contact with the AB Managed Volatility Equities?

Comments from SMSF Mates

Video Gallery

No current media available.

Historical Performance Commentary

Performance Commentary - June 30, 2023

• In June, the MVE—Class underperformed its benchmark, the S&P/ASX 300 Index, which was up 1.73% in Australian-dollar terms.

Detractors

• The materials and financials sectors detracted the most, while healthcare and consumer staples contributed.

• Health insurer Medibank detracted during the month as Australia’s banking regulator announced that it will apply a temporary additional capital adequacy requirement on Medibank following its review of the company’s cybercrime event. Medibank has a strong balance sheet and has sufficient existing capital to meet the adjustment. While this removes near-term upside of capital return to shareholders, precedent indicates that the additional capital requirement is likely to be lifted within 12 to 36 months. As the largest private health insurer in Australia, we believe Medibank should continue to benefit from positive industry trends, including growing participation and lower claims growth.

Contributors

• An underweight to biotechnology company CSL contributed as the company provided first-time earnings guidance for FY:24 that disappointed the market. Drivers of the downgrade to earnings guidance relative to market expectations included persistent cost headwinds in its core plasma business, as well as emerging revenue headwinds in its recently acquired renal pharmaceutical business as a key product nears loss of exclusivity. We continue to be cautious on CSL as it shifts into new therapeutic areas.

• Oracle contributed as technology stocks more broadly outperformed. The company reported better-than-expected earnings for its 2023 fiscal fourth quarter on the strength of its cloud computing offerings.

Performance Commentary - May 31, 2023

Performance Commentary - April 30, 2023

Performance Commentary - March 31, 2023

Performance Commentary - February 28, 2023

Performance Commentary - January 31, 2023

Performance Commentary - December 31, 2022

Kind words from Aussies managing
their own self funded futures

  • SMSF Mate is a unique website because it has ideas about how to approach SMSFs, insurance and other financial topics that come straight from first hand experience. It's much more useful than what you find on all the other financial websites that just offer generic info that you could easily get on the ATO's website. It's also nice to know there's no financial incentive behind the information, it's legitimately there to help people understand self-managed super funds and how to get the most out of them, not to get an affiliate commission from a broker or other financial services provider. The investment product information is also incredibly useful, I've never seen this kind of functionality on any other website that let's you look at such a wide range of products, sort by what info is most interesting or important to you, and subscribe to updates for different funds and financial products all in one place. Definitely worth checking out if you own or are considering an SMSF!

    David G, Self-Employed, SMSF Owner